BioCentury | Sep 29, 2020
Distillery Therapeutics

Blocking glucocorticoid signaling to increase checkpoint inhibitor sensitivity

...anti-PD-1 mAb or with systemic knockout of IL27RA...
...undisclosed cancer types.TARGET/MARKER/PATHWAY: Glucocorticoid receptor (GCCR); interleukin-27 receptor α (IL27RA); cytotoxic...
...Harvard Harvard Medical School Brigham and Women's Hospital Glucocorticoid receptor (GCCR) Interleukin-27(IL-27) receptor alpha (IL27RA) Cytotoxic...
BioCentury | Dec 21, 2018
Company News

Surface drops after deprioritizing lead product

...a mAb against ectonucleoside triphosphate diphosphohydrolase 1 (CD39; ENTPD1) and SRF388 is a mAb against IL-27...
BioCentury | Dec 19, 2018
Company News

Surface drops after deprioritizing lead product

...a mAb against ectonucleoside triphosphate diphosphohydrolase 1 (CD39; ENTPD1) and SRF388 is a mAb against IL-27...
BioCentury | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Mar 7, 2018
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest inhibiting IL-30 could help treat prostate cancer. In primary prostate cancer stem-like cells from a mouse model of the disease, an anti-IL-30 antibody or shRNA-mediated IL-30...
BioCentury | Mar 2, 2018
Preclinical News

Targeting IL-30 could treat prostate cancer

In a paper published in Cancer Research , Italian researchers found interleukin-30 (IL-30; IL-27p28) promotes growth and spread of prostate cancer stem-like cells and could be a target for treating the disease. The researchers, who are...
BioCentury | Oct 18, 2017
Translation in Brief

Neutrophil bias

...Researchers from the University of Texas Health Science Center have found that IL-27 promotes an anti-inflammatory...
...and reduced brain edema, and an anti-IL-27 antibody had the opposite effect. According to Aronowski, IL-27...
...IL-27. However, depletion of neutrophils in the mice only partially negated the therapeutic benefit of IL-27...
BioCentury | Sep 26, 2017
Distillery Therapeutics

Neurology

...INDICATION: Stroke Mouse studies suggest IL-27 could help treat intracerebral hemorrhage. In a mouse model of...
...intracerebral hemorrhage, IV injection of IL-27 30 minutes post-hemorrhage, followed by daily subcutaneous injections of IL-27...
...edema compared with vehicle. Next steps include testing in additional models of intracerebral hemorrhage. TARGET/MARKER/PATHWAY: Interleukin-27 (IL-27)...
BioCentury | Feb 28, 2017
Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Patient, cell culture and mouse studies suggest inhibiting IL-35 could help treat metastatic pancreatic ductal carcinoma (PDAC). In 123 PDAC patients, high levels of EBI3 and IL-12A in primary tumors were associated...
BioCentury | Jul 9, 2015
Targets & Mechanisms

Top Translational Targets, 2013-14

...in the clinic. Likewise, in autoimmune and infectious diseases, serum/glucocorticoid regulated kinase 1 (SGK1) and interleukin-27 (IL-27)...
Items per page:
1 - 10 of 20